CNSP — CNS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Cns Pharmaceuticals Announces FDA Approval Of IND Application For Its Brain Cancer Drug Candidate Berubicin
Brief: CNS Pharmaceuticals Announces FDA Filing Of IND For Its Brain Cancer Drug Berubicin
Brief: CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted For FDA Review
Brief: CNS Pharmaceuticals Completes Manufacturing Of Berubicin For Phase 2 Clinical Trial
Brief: CNS Pharma Completes U.S. Manufacturing Of Berubicin For Phase 2 Trial
Brief: CNS Pharmaceuticals Begins Manufacturing Of Berubicin In Europe
Brief: CNS Pharmaceuticals Files Prospectus Related To Offering Of 2.1 Million Shares By Selling Stockholder
Brief: Cns Pharmaceuticals Says GMP Manufacturer Partner Got Certificate Of Analysis For Active Pharma Ingredient
Brief: Cns Pharmaceuticals Files For Offer And Sale Of Up To 2.1 Mln Shares Of Common Stock By Lincoln Park Capital Fund - SEC Filing
Brief: CNS Pharmaceuticals Says Lincoln Park To Purchase Up To $15 Mln Worth Of Co's Common Stock
Brief: CNS Pharma Announces Agreement to Extend Term of CEO John Climaco
CNS Pharma: Rises on achieving milestones for lead tumor treatment
Brief: Cns Pharmaceuticals- Update On Progress For U.S. Manufacturing Of Berubicin
Brief: Cns Pharmaceuticals Announces Appointment Of Patrick Wen To Science Advisory Board
Brief: Cns Provides FDA Update On Ind Filing
Brief: CNS Pharmaceuticals Says Engaged CRO For Phase 2 Berubicin Trials
Brief: Cns Pharmaceuticals Completes Drug Product Manufacturing Strategy For Berubicin
Brief: CNS Pharmaceuticals Engages Berry Consultants To Advise Phase 2 Trial Design
Brief: CNS Announces FDA Has Granted Orphan Drug Designation For Brain Cancer Drug Berubicin